Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25611104 | 0.88 | POLB (0.57) | RXFP1LMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL24209799 | 0.86 | RXFP1 (0.82) | RXFP1LMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL24029049 | 0.85 | POLB (0.66) | POLBMEN1KMT2A | |
| SCHEMBL24209791 | 0.73 | ALDH1A1 (0.66) | LMNASMN1; SMN2POLBHPGDMEN1 | |
| SCHEMBL3868831 | 0.68 | GAA (0.91) | LMNAPOLBTP53MAPTGAA | |
| SCHEMBL24029355 | 0.66 | POLB (0.50) | RXFP1LMNASMN1; SMN2POLBMAPT | |
| SCHEMBL24209798 | 0.65 | SMN1; SMN2 (0.65) | RXFP1LMNASMN1; SMN2POLBUSP2 | |
| SCHEMBL22010389 | 0.63 | HPGD (0.69) | POLBMAPTHPGDMEN1KMT2A | |
| SCHEMBL24210198 | 0.63 | KDM4E (0.64) | LMNASMN1; SMN2POLBUSP2MAPT | |
| SCHEMBL24210197 | 0.63 | ALDH1A1 (0.83) | LMNASMN1; SMN2POLBUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | RXFP1 4623/4885LMNA 3135/4885SMN1; SMN2 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.